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Background: This study aimed to evaluate the prevalence of parvovirus B19 anti-
bodies in children and young adults aged ≤ 30 years old in Taiwan.
Methods: Stored serum samples from healthy volunteers aged 1−29 years in Taipei 
were randomly selected and tested for antiparvovirus B19 immunoglobulin G by 
enzyme immunoassay.
Results: A total of 277 serum samples were tested. The overall seroprevalence of 
parvovirus B19 in Taiwanese children and young adults was 23.1% (64/277) in 2004. 
The positive rate increased slightly with age; it ranged from 15.0% in those aged 
1−4 years to 30.8% in those aged 25−29 years (trend test, p = 0.01). The age-adjusted 
anti-B19 immunoglobulin G seropositive rate was slightly higher in males (27.8%) than 
in females (18.8%; adjusted odds ratio: 0.56; 95% confidence interval: 0.32−0.99).
Conclusion: Most children and young adults in Taipei City are not immune to parvo-
virus B19, suggesting that no parvovirus B19 epidemic has occurred in the last few 
decades.
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1.  Introduction
Parvovirus B19 is a small DNA virus with a single-
stranded, linear genome transmitted among hu-
mans via respiratory droplets. B19 infections are 
most commonly recognized as an erythema infec-
tiosum in children.1,2 Other modes of transmission 
include percutaneous exposure to blood products 
and vertical transmission from the mother to fetus.2 
The incubation period is usually 4−14 days but can 
be as long as 21 days.2
The clinical manifestations associated with B19 
infection vary greatly. A mild clinical manifestation, 
called erythema infectiosum, is most common in in-
fected children.2 However, severe diseases can occur 
in high-risk groups. These diseases include aplastic 
anemia or prolonged bone marrow suppression in 
patients with hematological disorders or immuno-
compromised patients. Parvovirus B19 infection is 
also responsible for 6−9% of fetal losses in pregnant 
women during the first 20 weeks of gestation.1,3,4
In temperate zones, parvovirus B19 infection is 
common, with a peak incidence in 5−15-year-old 
children.5−7 However, it seems that there were no 
outbreaks of rash illness in children in tropical 
countries such as Singapore and Taiwan in the late 
1990s.8,9 Lin et al9 determining the extent of B19 
virus infections in Taiwan and found that the over-
all prevalence of anti-B19 immunoglobulin G (IgG) 
was 32.8% in the early 1980s. The introduction of 
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widespread measles mumps and rubella vaccination 
in Taiwan in 1992 means that the infectious rash ill-
nesses in children are likely to be diseases other than 
measles and rubella.1 This study aimed to reevalu-
ate the seroepidemiological surveys in children and 
young adults and to identify the possible susceptible 
groups if parvovirus B19-related epidemics do occur.
2.  Materials and Methods
2.1.  Samples
A total of 277 serum samples were randomly selected 
by age category from the 18,779 original samples 
used to study the epidemiology of hepatitis B virus 
by Ni et al in 2004.10 The use of the stored serum sam-
ple for this study was reviewed and approved by the 
Ethics Committee of the National Taiwan University 
Hospital. Each stored specimen had a unique identi-
fier plus sex and age. Approximately 50 samples were 
randomly selected for each age group (Table 1). All 
study participants were healthy volunteers aged 1−29 
years. Participants were recruited from health care 
clinics, schools, institutes or workplaces; all par-
ticipants residing in Taipei. The study was approved 
by the Clinical Research Ethics Committee of the 
Centers for Disease Control, Taiwan.
2.2.  Parvovirus B19 detection assay
B19 IgG was detected by a sandwich enzyme im-
munoassay according to the manufacturer’s instruc-
tions (Biotrin International, Dublin, Ireland). Briefly, 
100 μL of each standard and 1:100-diluted samples 
were added to the parvovirus B19 recombinant VP2 
protein-coated microtiter plate wells. After incu-
bation at room temperature for 1 hour, the wells were 
washed; 100 μL of peroxidase-labeled rabbit anti-
human IgG was added and incubated for 30 minutes 
at 35−39ºC. After washing, 100 μL of substrate so-
lution (tetramethylbenzidine) was added and the color 
was developed for 30 minutes at 35−39ºC. After 
adding 100 μL of stop reagent (0.5 M sulfuric acid), 
the optical density was read immediately at a filter 
wavelength of 450 nm with a microplate spectro-
photometer. The cut-off values for a positive test 
were calculated as described by the manufacturer.
2.3.  Statistical analysis
Odds ratios (OR) and 95% confidence intervals (CI) 
were calculated by unconditional logistic regression. 
The p value for the trend test was measured as the 
level of significance of the regression coefficient 
for each ordinary variable in the logistic regression 
model. Epi Info version 3.4.3 (Centers for Disease 
Control and Prevention, Atlanta, GA, USA) was used 
for all statistical analyses, and p < 0.05 was consid-
ered statistically significant.
3.  Results
Sixty-four of the 277 (23.1%) serum samples tested 
positive for the B19 IgG antibody. The overall sero-
positive rate of IgG for males and females was 27.8% 
(37/133) and 18.8% (27/144), respectively. After ad-
justing for age, the seropositive rate in females was 
slightly lower than that in males (adjusted OR: 0.54; 
95% CI: 0.30−0.97). As shown in Table 1, the sero-
prevalence of parvovirus B19 increased slowly with 
Table 1  Prevalence of parvovirus B19 immunoglobulin G antibodies in children and young adults according to age 
groups in Taiwan, 2004
 Samples tested (n) Positive samples n (%) OR 95% CI AOR 95% CI
Sex
  Male 133 37 (27.8) 1.00 Reference 1.00* Reference
  Female 144 27 (18.8) 0.5988 0.34−1.05 0.54† 0.30−0.97
Age group (yr)
  1−4  40  6 (15.0) 1.00 Reference 1.00‡ Reference
  5−9  50 4 (8.0) 0.49 0.13−1.88 0.50 0.13−1.91
  10−14  50 18 (36.0) 3.19† 1.12−9.04 3.30† 1.15−9.45
  15−19  45 10 (22.2) 1.62 0.53−4.95 1.62 0.53−4.99
  20−24  40 10 (25.0) 1.89 0.61−5.82 1.94 0.62−6.01
  25−29  52 16 (30.8) 2.52 0.88−7.19 2.86 0.99−8.30
Trend test   p = 0.02  p = 0.01
Total 277 64 (23.1)
*Adjusted for age; †statistically significant; ‡adjusted for sex. OR = odds ratio; CI = confidence interval; AOR = adjusted odds ratio.
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age and ranged from 15.0% in participants aged 
1−4 years to 30.8% in those aged 25−29 years (trend 
test, p = 0.02; sex-adjusted trend test, p = 0.01). An 
unexpectedly high positive rate (36.0%) was noted 
in participants aged 10−14 years.
After regrouping the results according to the 
method used by Lin et al,9,11 the seropositive rates 
for parvovirus B19-IgG were 20.0% (28/140), 22.2% 
(10/45), and 28.3% (26/92) in the participants aged 
1−14 years, 15−19 years, and 20−29 years, respec-
tively (Table 29,11). Using this grouping method, our 
results showed the same pattern as that reported 
in 1986.11 The seroprevalence of parvovirus B19 in-
creases with age. However, the trend test showed 
a significant result only in tests done in 1986. As 
shown in Figure 1, the seropositive rate in 2004 was 
significantly higher (20.0%) in participants aged 
1−14 years in comparison to the corresponding rate 
(10.3%) in 1986 (OR: 2.16; 95% CI: 1.05−4.48). In 
contrast, there were no differences in the seropos-
itive rates among participants aged 15−19 years or 
20−29 years between 1986 and 2004.
4.  Discussion
Parvovirus B19 infections are ubiquitous world-
wide. Normally, the prevalence of parvovirus B19 
antibodies increases with age and varies with pop-
ulation densities, compliance with hand hygiene, and 
environmental cleaniness,12 which are all closely 
related to the presence or absence of outbreaks.13,14 
In earlier reports from Australia, the parvovirus se-
ropositive rates were about 10% in preschool chil-
dren, 20−30% in school-age children, 50−60% in adults, 
and higher in older age groups.15 However, sero-
positive rates as high as 56−80% have been reported 
in teenagers in England and Brazil.5,16 Decreased or 
delayed levels of seropositivity for parvovirus B19 
infections in populations could be associated with a 
lack of major outbreaks of parvovirus infections.8,17
In the current study, the parvovirus B19 sero-
positive rate in children and young adults was low, 
suggesting that parvovirus B19 infections have be-
come less common in Taiwan in the past few dec-
ades, similar to recent reports from other countries.15 
Like other viral diseases transmitted by airway drop-
lets, children and young adults are the most vul-
nerable groups. This is partly because participants 
in this age group are naïve to the virus and have not 
yet established specific immunity. The proportion of 
participants showing immunity increases gradually 
with age. The annual seroconversion rate in elemen-
tary schools was reported to be around 5% in the 
1990s in the United States.12
The reason for the unexpectedly high positive rate 
observed in children aged 10−14 years is unclear. 
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Figure 1 Prevalence of parvovirus B19-specific immu-
noglobulin G in children and young adults in 19869,11 and 
2004. For children aged 1−14 years, the seroprevalence 
was 10.3% and 20.0% in 1986 and 2004, respectively; a 
statistically significant difference was observed [odds ratio 
(OR) = 2.16; 95% confidence interval (CI): 1.05−4.48]. In 
contrast, there were no differences in the prevalence of 
B19 immunoglobulin G over time among participants aged 
15−19 years (OR: 1.51; 95% CI: 0.65−3.54) or 20−29 years 
old (OR: 1.28; 95% CI: 0.69−2.40). Error bars represent 
95% CI. *Statistically significant.
Table 2  Age-specific prevalence of parvovirus B19 immunoglobulin G antibodies in Taiwan in 19869,11 and 2004
 1986 2004
 Samples positive/ 
OR
 
95% CI
 Samples positive/  
OR 95% CI
 tested n (%)   tested n (%)
Age group (yr)
  1−14 12/116 (10.3) 1.0* Reference 28/140 (20.0) 1.0* Reference
  15−19 20/126 (15.9) 1.6 0.8−3.5  10/45 (22.2) 1.1 0.5−2.6
  20−29 27/115 (23.5) 2.7† 1.3−5.6  26/92 (28.3) 1.7 0.9−3.1
Trend test  p < 0.01   p = 0.11
Total 59/357 (16.5)   64/277 (23.1)
*Adjusted for sex; †statistically significant. OR = odds ratio; CI = confidence interval.
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Possible explanations include the existence of a 
preceding small-scale cluster parvovirus B19 out-
break in that age group. This seems likely because 
the positive rate in those aged 1−14 years was 
higher in this study than in the survey done in 1986. 
However, because the sample size was small, we 
cannot exclude the possibility of sampling bias. 
Likewise, the small difference in the seropositive 
rate of participants aged 1−4 years or 5−9 years was 
probably because of the small sample size. When 
we regroup the study participants as shown in 
Table 29,11 and Figure 1,9,11 the trend is more evident 
that the positive rate increases with age.
Although parvovirus infection is self-limited in 
healthy individuals, it is a major threat during preg-
nancy and is an important cause of early fetal loss. 
In England, maternal infection with parvovirus B19 
is estimated to occur in approximately 1 in 400 preg-
nancies, and fetal death was estimated to occur in 
9% of these cases.18 In the current study, up to 70% 
of women aged 29 years or less were susceptible to 
parvovirus B19 infections. Continuous improvements 
in public and personal hygiene practices should 
keep the prevalence of parvovirus B19 immunity 
low. However, because fewer females than males 
have parvovirus antibodies, as shown in this study, 
we are concerned about the susceptibility of preg-
nant women to parvovirus B19 infections and the 
possible consequences of such infections. Women 
who work in healthcare settings and daycare cent-
ers are at increased risk of acquiring this infection, 
as are women working in different households.19 
Women of childbearing age and obstetric providers 
are advised to become more familiar with the clin-
ical presentation of a parvovirus B19 infection and 
its possible consequences.
5.  Conclusions
In conclusion, the rate of parvovirus B19 infections 
in children and young adults was low in Taiwan in the 
past few decades. People aged ≤ 30 years are highly 
susceptible to parvovirus B19 infections. Outbreaks 
of rash illness in children and young adults should 
be serologically investigated for parvovirus B19.
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